Sofgen Pharma Secures $130 Million in Equity Investment and Completes Comprehensive Debt Restructuring, as New Investors Take Over Strategic Leadership
New Investors Take Over the Strategic Leadership as Headquarters Move to Bogotá, Marking the Start of a New Chapter of Growth, Execution, and Transformation under Enhanced Governance Company Accelerates Turnaround with Leadership Changes, Regional Realignment, Sale of Non-Core Assets and Renewed
Sofgen Pharma 20-F
This Annual Report contains the annual audited consolidated financial statements of Procaps Group, S.A. as of December 31, 2023, 2022 restated and January 1, 2022 restated, and for the years ended December 31, 2023, 2022 restated and 2021 restated (the “Annual Audited Consolidated Financial Statements”).